FindTrial
Sign In

Development of a new immunochemistry method using antibodies of proteins related pancreatic cancer in the pancreatic cancer cell

Study of optimal immunochemistry method using antibodies of methionyl-tRNA synthetase 1 (MARS1) in the pancreatic cancer cell

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CRIS
Registry ID
KCT0006134
Enrollment
50
Registered
2021-05-12
Start date
2021-05-17
Completion date
Unknown
Last updated
2021-05-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Yonsei University Health System, Gangnam Severance Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients with pancreatic cancer confirmed by imaging (CT, MRI, PET-CT) 2. Patients with pancreatic cancer diagnosed using cytology by endoscopic ultrasound 3. Patients who underwent surgical treatment with pancreatic cancer

Exclusion criteria

Exclusion criteria: 1. Minors under the age of 19, vulnerable subjects such as illiteracy 2. Excludes necrotic specimens

Design outcomes

Primary

MeasureTime frame
Compare the results of immunofluorescence staining and immunochemical staining according to the type of brush cell slide (thinprep, surepath, direct smear) to confirm the correlation with the final diagnosis name. (With a correlation of 80% or more, the optimal staining method with the highest correlation is identified.)—

Secondary

MeasureTime frame
Efficacy of staining method(the sensitivity, specificity, accuracy, positive predictive value and negative predictive value)—

Countries

Korea, Republic of

Contacts

Public ContactSung Ill Jang

Yonsei University Health System, Gangnam Severance Hospital

aerojsi88@gmail.com+82-2-2019-3580

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026